International Journal of Preclinical and Clinical Research

References

1. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care. 1999;22:345. Available from: https://dx.doi.org/10.2337/diacare.22.2.345
2. Freeman H, Cox RD. Type 2 diabetes: A cocktail of genetic discovery. Hum Mol Genet. 2006;15:202–209.
3. Klein R. Hyperglycemie and microvascular and macrovascular disease in Diabetes. Diabetes Care. 1995;18(2):258–268. Available from: https://dx.doi.org/10.2337/diacare.18.2.258
4. Stumvoll M, Goldstein BJ, Haeften TWv. Type 2 diabetes: Principles of pathogenesis and therapy. The Lancet. 2005;365(9467):1333–1346. Available from: https://dx.doi.org/10.1016/s0140-6736(05)61032-x
5. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients. Diabetes. 2001;50(3):609–613. Available from: https://dx.doi.org/10.2337/diabetes.50.3.609
6. Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157. Available from: https://dx.doi.org/10.1053/j.gastro.2007.03.054
7. LARSSON H, HOLST JJ, AHRÉN B. Glucagon‐like peptide‐1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiologica Scandinavica. 1997;160(4):413–422. Available from: https://dx.doi.org/10.1046/j.1365-201x.1997.00161.x
8. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM. A meta-analysis of the effect of glucagon-like peptide-1 amide on ad libitum energy intake in humans. J ClinEndocrinolMetab. 2001;86:4382–4389.
9. Haffner SM. Relationship of metabolic risk factors and development of cardiovascular disease and Diabetes. Obesity. 2006;14(6s):121S–127S. Available from: https://dx.doi.org/10.1038/oby.2006.291
10. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Williams B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126–1131.
11. Rask E, Olsson T, Soderberg S, Johnson O, Seckl J, Holst JJ, et al. Impaired Incretin response After a Mixed Meal Is Associated With Insulin Resistance in Nondiabetic Men. Diabetes Care. 2001;24(9):1640–1645. Available from: https://dx.doi.org/10.2337/diacare.24.9.1640
12. Raun K, Voss PV, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not. Diabetes. 2007;56(1):8–15. Available from: https://dx.doi.org/10.2337/db06-0565
13. Toft-Nielsen MB, Damholt MB, Madsbad S. Determinants of impaired secretion of GLP-1 in type 2 diabetic patients. J ClinEndocrinolMetab. 2001;86:3717–3723.
14. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. American Journal of Physiology-Endocrinology and Metabolism. 2004;287(2):E199–E206. Available from: https://dx.doi.org/10.1152/ajpendo.00545.2003
15. Harder H, Nielsen L, Thi TDT, Astrup A. The Effect of Liraglutide, a Long-Acting Glucagon-Like Peptide 1 Derivative, on Glycemic Control, Body Composition, and 24-h Energy Expenditure in Patients With Type 2 Diabetes. Diabetes Care. 2004;27(8):1915–1921. Available from: https://dx.doi.org/10.2337/diacare.27.8.1915
16. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nature Reviews Endocrinology. 2009;5(5):262–269. Available from: https://dx.doi.org/10.1038/nrendo.2009.48
17. Madsen K, Knudsen LB, Agersøe H. Structure-activity and protraction relationship of long-acting glucagon-like peptide 1 derivatives: Importance of fatty-acid length, polarity and bulkiness. J Med Chem. 2007;50:126–132.
18. Muller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes: Response to carbohydrate and protein ingestion. N Engl J Med. 1970;283:109–115.
19. Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia. 1994;37:543–551.
20. Cummings BP, Stanhope KL, Graham JL, Baskin DG, Griffen SC, Nilsson C, et al. Chronic Administration of the Glucagon-Like Peptide-1 Analog, Liraglutide, Delays the Onset of Diabetes and Lowers Triglycerides in UCD-T2DM Rats. Diabetes. 2010;59(10):2653–2661. Available from: https://dx.doi.org/10.2337/db09-1564
21. Raun K, Voss Pv, Knudsen LB. Liraglutide, a once-daily human Glucagon-like Peptide-1 Analog, minimizes food intake in severely obese minipigs. Obesity. 2007;15(7):1710–1716. Available from: https://dx.doi.org/10.1038/oby.2007.204
22. González C, Beruto V, Keller G, Santoro S, Girolamo GD. Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide. Expert Opinion on Investigational Drugs. 2006;15(8):887–895. Available from: https://dx.doi.org/10.1517/13543784.15.8.887
23. Wajcberg E, Amarah A. Liraglutide in the management of type 2 diabetes. Drug Design, Development and Therapy. 2010;4:279. Available from: https://dx.doi.org/10.2147/dddt.s10180
24. RJD. Molecular, pharmacological, and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol. 2009;297:137–140.
25. Triplitt C, Wright A, Chiquette E. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: Potential new therapies for type 2 diabetes mellitus. Pharmacotherapy. 2006;26(3):360–374. doi: 10.1592/phco.26.3.360
26. Malm-Erjefält M, Bjørnsdottir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, et al. Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase. Drug Metabolism and Disposition. 2010;38(11):1944–1953. Available from: https://dx.doi.org/10.1124/dmd.110.034066
27. Lee PH, Stockton MD, Franks AS. Acute Pancreatitis Associated with Liraglutide. Annals of Pharmacotherapy. 2011;45(4):541. Available from: https://dx.doi.org/10.1345/aph.1p714
28. Knezevich E, Crnic T, Kershaw S, Drincic A. Liraglutide-associated acute pancreatitis. American Journal of Health-System Pharmacy. 2012;69(5):386–389. Available from: https://dx.doi.org/10.2146/ajhp110221
29. Parks M, Rosebraugh C. Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy. New England Journal of Medicine. 2010;362(9):774–777. Available from: https://dx.doi.org/10.1056/nejmp1001578
30. Knudsen BL, Madsen LW, Andersen S. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473–1486.
31. Hegedus L, Moses AC, Zdravkovic M. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analogue. liraglutide. J ClinEndocrinolMetab. 2011;96:853–60.
32. Madsen LW, Knauf JA, Gotfredsen C, Pilling A, Sjögren I, Andersen S, et al. GLP-1 receptor agonists and the Thyroid: C-Cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 2012;153(3):1538–1547. Available from: https://dx.doi.org/10.1210/en.2011-1864
33. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2010;33(6):1173–1175. Available from: https://dx.doi.org/10.2337/dc09-1203
34. Kelly AS, Metzig AM, Rudser KD. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity. 2012;20:364–370.
35. Sze L, Purtell L, Jenkins A. Effects of a single dose of exenatide on appetite, gut hormones and glucose homeostasis in adults with Prader-Willi syndrome. J ClinEndocrinolMetab. 2011;96:1314–1329.
36. Varanasi A, Bellini N, Rawal D, Vora M, Makdissi A, Dhindsa S, et al. Liraglutide as additional treatment for type 1 diabetes. European Journal of Endocrinology. 2011;165(1):77–84. Available from: https://dx.doi.org/10.1530/eje-11-0330
37. Kielgast U, Krarup T, Holst JJ, Madsbad S. Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual  -Cell Function. Diabetes Care. 2011;34(7):1463–1468. Available from: https://dx.doi.org/10.2337/dc11-0096
38. Aaboe K, Krarup T, Madsbad S, Holst JJ. GLP-1: physiological effects and potential therapeutic applications. Diabetes, Obesity and Metabolism. 2008;10(11):994–1003. Available from: https://dx.doi.org/10.1111/j.1463-1326.2008.00853.x
39. Nauck M, Hompesch M, Filipczak R, Le T, Zdravkovic M, Gumprecht J. Five Weeks of Treatment with the GLP-1 Analogue Liraglutide Improves Glycaemic Control and Lowers Body weight in Subjects with Type 2 Diabetes. Experimental and Clinical Endocrinology & Diabetes. 2006;114(08):417–423. Available from: https://dx.doi.org/10.1055/s-2006-924230
40. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, et al. Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes. Diabetes Care. 2007;30(6):1608–1610. Available from: https://dx.doi.org/10.2337/dc06-2593
41. Kapitza C, Flint A, Spitzer H, Hindsberger C, Zdravkovic M. The effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. Diabetes. 2008;57:593.
42. Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the Pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. The Journal of Clinical Pharmacology. 2006;46(6):635–641. Available from: https://dx.doi.org/10.1177/0091270006288215
43. Jendle J, Nauck MA, Mathews D. The reduction of body weight with liraglutide, once-daily human GLP-1 analogue in type 2 diabetes, primarily comes from fat tissue and the fat tissue lost in predominantly visceral fat. Diabetologia. 2008;51(1 Suppl.):S318.
44. Colagiuri S, Frid A, Zdravkovic M, Le-Thi T, Vaag A. The once-daily human GLP-1 analogue liraglutide reduces systolic blood pressure in patients with type 2 diabetes. Diabetes. 2008;57:164–169.
45. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of Liraglutide, Glimepiride, and Placebo, all in combination with Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care. 2009;32(1):84–90. Available from: https://dx.doi.org/10.2337/dc08-1355
46. Courrèges JP, Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabetic Medicine. 2008;25(9):1129–1131. Available from: https://dx.doi.org/10.1111/j.1464-5491.2008.02484.x
47. Garber A, Henry R, Ratner R. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomized, 52 week, phase 3, double-blind, parallel treatment trial. Lancet. 2009;373:473–481.
48. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care. 2004;27(6):1335–1342. Available from: https://dx.doi.org/10.2337/diacare.27.6.1335
49. Chen YE, Drucker DJ. Tissue-specific expression of unique mRNAs that encode a. proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem. 1997;272:4108–4115.
50. Malone J, Trautmann M, Wilhelm K, Taylor K, Kendall DM. Exenatide once weekly for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs. 2009;18(3):359–367. Available from: https://dx.doi.org/10.1517/13543780902766802
51. Kim D, MacConell L, Zhuang D, Kothare PA, Trautmann M, Fineman M, et al. Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes. Diabetes Care. 2007;30(6):1487–1493. Available from: https://dx.doi.org/10.2337/dc06-2375
52. Buse JB, Drucker DJ, Taylor KL, Kim T, Walsh B, Hu H, et al. DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks. Diabetes Care. 2010;33(6):1255–1261. Available from: https://dx.doi.org/10.2337/dc09-1914
53. Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis C, et al. DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared with Exenatide twice daily in patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2011;96(5):1301–1310. Available from: https://dx.doi.org/10.1210/jc.2010-2081
54. Bergenstal RM, Wysham C, Macconell L. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of a. type 2 diabetes (DURATION-2): a randomised trial. Lancet. 376:431–439.
55. Wysham C, Bergenstal R, Malloy J, Yan P, Walsh B, Malone J, et al. DURATION-2: Efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. Diabetic Medicine. 2011;28(6):705–714. Available from: https://dx.doi.org/10.1111/j.1464-5491.2011.03301.x
56. Drucker DJ, Buse JB, Taylor K. Exenatide once-weekly vs. twice daily for the treatment of type 2 diabetes: a randomised open labelled non-inferiority trial. Lancet. 2008;372:1240–1250.
57. Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. British Journal of Clinical Pharmacology. 2009;68(6):898–905. Available from: https://dx.doi.org/10.1111/j.1365-2125.2009.03536.x
58. Flint A, Nazzal K, Jagielski P, Hindsberger C, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutide. British Journal of Clinical Pharmacology. 2010;70(6):807–814. Available from: https://dx.doi.org/10.1111/j.1365-2125.2010.03762.x
59. Ratner RE, Rosenstock J, Boka G, . Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. Diabetic Medicine. 2010;27(9):1024–1032. Available from: https://dx.doi.org/10.1111/j.1464-5491.2010.03020.x
60. Christensen M, Knop FK, Vilsbøll T. The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. Expert Review of Endocrinology & Metabolism. 2011;6(4):513–525. Available from: https://dx.doi.org/10.1586/eem.11.30
61. Matthews JE, Stewart MW, Boever EHD, Dobbins RL, Hodge RJ, Walker SE, et al. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with Type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism. 2008;93(12):4810–4817. Available from: https://dx.doi.org/10.1210/jc.2008-1518
62. Seino Y, Nakajima H, Miyahara H. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin. 2009;25:3049–3057.
63. Onge ELS, Miller SA. Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes. Expert Opinion on Biological Therapy. 2010;10(5):801–806. Available from: https://dx.doi.org/10.1517/14712598.2010.481281
64. Tomkin GH. Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for the potential treatment of type 2 diabetes. CurrOpinMolTher. 2009;11:579–588.
65. Retterstol K. Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue. Expert OpinInvestig Drugs. 2009;18:1405–1411.
66. Kapitza C, Heise T, Birman P, Jallet K, Ramis J, Balena R. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. Diabetic Medicine. 2009;26(11):1156–1164. Available from: https://dx.doi.org/10.1111/j.1464-5491.2009.02854.x
67. Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Treatment With the Human Once-Weekly Glucagon-Like Peptide-1 Analog Taspoglutide in Combination With Metformin Improves Glycemic Control and Lowers Body Weight in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone: A double-blind placebo-controlled study. Diabetes Care. 2009;32(7):1237–1243. Available from: https://dx.doi.org/10.2337/dc08-1961
68. Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin M, Balena R. Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study1,2. Diabetic Medicine. 2010;27(5):556–562. Available from: https://dx.doi.org/10.1111/j.1464-5491.2010.02990.x
69. Doggrell SA. Semaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist. Expert Opinion on Drug Metabolism & Toxicology. 14(3):371–377.